Drug price negotiation for ‘Tagrisso’ called off once again, brings controversy of special treatment for multinational pharma

The drug price negotiation for AstraZeneca Korea’s ‘Tagrisso,’ a treatment for non-small cell lung cancer with T790M mutations, has been called off once again, which raised controversy about special treatments on the multinational pharmaceutical company. It is the first time for a final negotiation to be called off for twice by the Minister of Health and Welfare’s authority.

According to the i...